



2017

Benzylideneoxymorphone: A New Lead for Development of Bifunctional Mu/Delta Opioid Receptor Ligands

Jason R. Healy

Padmavani Bezawada

Nicholas W. Griggs

Andrea L. Devereaux

Rae Reiko Matsumoto

Touro University California, rae.matsumoto@tu.edu

See next page for additional authors

Follow this and additional works at: https://touro scholar.touro.edu/tuccop_pubs



Part of the [Biochemistry Commons](#), and the [Pharmaceutics and Drug Design Commons](#)

Recommended Citation

Healy, J. R., Bezawada, P., Griggs, N. W., Devereaux, A. L., Matsumoto, R. R., Traynor, J. R., . . . Cunningham, C. W. (2017). Benzylideneoxymorphone: A new lead for development of bifunctional mu/delta opioid receptor ligands. *Bioorganic & Medicinal Chemistry Letters*, 27(3), 666-669.

Authors

Jason R. Healy, Padmavani Bezawada, Nicholas W. Griggs, Andrea L. Devereaux, Rae Reiko Matsumoto, John R. Traynor, and Christopher W. Cunningham

Accepted Manuscript

Benzylideneoxymorphone: A new lead for development of bifunctional mu/delta opioid receptor ligands

Jason R. Healy, Padmavani Bezawada, Nicholas W. Griggs, Andrea L. Devereaux, Rae R. Matsumoto, John R. Traynor, Andrew Coop, Christopher W. Cunningham

PII: S0960-894X(16)31209-4
DOI: <http://dx.doi.org/10.1016/j.bmcl.2016.11.057>
Reference: BMCL 24452

To appear in: *Bioorganic & Medicinal Chemistry Letters*

Received Date: 14 September 2016
Revised Date: 20 November 2016
Accepted Date: 21 November 2016

Please cite this article as: Healy, J.R., Bezawada, P., Griggs, N.W., Devereaux, A.L., Matsumoto, R.R., Traynor, J.R., Coop, A., Cunningham, C.W., Benzylideneoxymorphone: A new lead for development of bifunctional mu/delta opioid receptor ligands, *Bioorganic & Medicinal Chemistry Letters* (2016), doi: <http://dx.doi.org/10.1016/j.bmcl.2016.11.057>


This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2016. This manuscript version is made available under the CC-BY-NC-ND 4.0 license <http://creativecommons.org/licenses/by-nc-nd/4.0/>



Benzylideneoxymorphone: A new lead for development of bifunctional mu/delta opioid receptor ligands

Jason R. Healy, Padmavani Bezawada, Nicholas W. Griggs, Andrea L. Devereaux, Rae R. Matsumoto, John R. Traynor, Andrew Coop, Christopher W. Cunningham



ACCEPTED MANUSCRIPT

Benzylideneoxymorphone: A new lead for development of bifunctional mu/delta opioid receptor ligands

Jason R. Healy^{a,b}, Padmavani Bezawada^c, Nicholas W. Griggs^d, Andrea L. Devereaux^e, Rae R. Matsumoto^{a,f}, John R. Traynor^d, Andrew Coop^c, Christopher W. Cunningham^{e,*}

^aDepartment of Basic Pharmaceutical Sciences, West Virginia University School of Pharmacy, 2036 Health Sciences North, Morgantown, WV 26506 USA

^bDepartment of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, 1170 Main Bldg., 132 S. 10th St., Philadelphia, PA 19107 USA

^cDepartment of Pharmaceutical Sciences, University of Maryland School of Pharmacy, 20 Penn Street, Baltimore, MD 21201 USA

^dDepartment of Pharmacology, University of Michigan Medical School, 1220A MSRB, Ann Arbor, MI 48109 USA

^eDepartment of Pharmaceutical Sciences, Concordia University Wisconsin School of Pharmacy, 12800 N. Lake Shore Drive, Mequon, WI 53097, USA

^fDepartment of Biological and Pharmaceutical Sciences, Touro University California College of Pharmacy, 1310 Club Drive, Vallejo, CA 94592 USA

Keywords:

mu opioid receptor
delta opioid receptor
analgesic tolerance
oxymorphone
benzylideneoxymorphone

Abstract

Opioid analgesic tolerance remains a considerable drawback to chronic pain management. The finding that concomitant administration of delta opioid receptor (DOR) antagonists attenuates the development of tolerance to mu opioid receptor (MOR) agonists has led to interest in producing bifunctional MOR agonist/DOR antagonist ligands. Herein, we present 7-benzylideneoxymorphone (**6**, UMB 246) displaying MOR partial agonist/DOR antagonist activity, representing a new lead for designing bifunctional MOR/DOR ligands.

* Corresponding author. Tel.: +1-262-243-2792; fax: +1-262-243-2920; e-mail: chris.cunningham@cuw.edu

Chronic severe pain is a considerable burden facing public health, costing the United States an estimated \$560-635 billion in health care costs and loss of productivity in 2011.¹ Opioid analgesics remain the standard treatment for severe pain, due to their ability to inhibit nociceptive processing and maintain the patient in a state of well-being.² Despite their benefits and widespread use, long-term use of opioids such as morphine and oxycodone is hindered by the rapid development of analgesic tolerance. Tolerance to intestinal motility does not develop as rapidly as analgesic tolerance; this “differential tolerance” results in severe constipation arising from the increased doses required to compensate for the diminished analgesic effect.³ Analgesics that produce a blunted tolerance effect would be expected to lower healthcare costs and provide beneficial outcomes to patients.

Three opioid receptor (OR) types have been cloned and characterized, namely mu (MOR), delta (DOR), and kappa (KOR), and are members of the G protein-coupled receptor (GPCR) superfamily. All approved opioid analgesics are MOR agonists, and produce analgesic and euphoric effects. Bifunctional opioid receptor ligands possessing dual profiles of OR type agonism and antagonism may also offer certain pharmacologic advantages. For example, buprenorphine (Suboxone; Subutex) is a MOR partial agonist/KOR antagonist that is used as an alternative to methadone for treating opioid dependence.⁴

There is considerable evidence that concomitant DOR antagonism attenuates the development of tolerance to MOR agonists. Studies using DOR knockout mice⁵ and DOR-specific antibodies,⁶ as well as pharmacologic inhibition of DOR using naltrindole,⁷ support this hypothesis. These proof-of-concept studies have led to the development of ligands that are bifunctional MOR agonists and DOR antagonists. Building upon the success of DIPP-NH₂[Ψ], the first bifunctional, tetrapeptide MOR agonist/DOR antagonist to produce antinociception with a low propensity to produce tolerance and dependence,⁸ several small-molecule bifunctional MOR/DOR probes have been produced (Figure 1) and demonstrate efficacy *in vitro* and *in vivo*.⁹⁻¹² To overcome limitations of solubility, oral bioavailability, and receptor-type potency, we have set out to identify new chemical leads for bifunctional MOR agonist/DOR antagonist ligands.




Figure 1. Three examples of small-molecule, bifunctional MOR agonist/DOR antagonist lead molecules.¹⁰⁻¹²

The DOR antagonist benzyldenentrexone (BNTX, Figure 2) was first described as a DOR-selective antagonist.¹³ This compound was rationalized using the “message-address concept,” whereby the naltrexone “message” was selectively targeted to DOR by the 7-benzylidene “address.” Subsequent reports^{14,15} demonstrate BNTX binds with similar affinity to MOR and antagonizes the effects of MOR agonists with similar potency as DOR agonists.¹⁶ Thus, we consider BNTX to be a MOR/DOR antagonist. The *N*-substituent frequently modulates efficacy in the 4,5-epoxymorphinan series of MOR analgesics. According to a ligand-based, quantitative conformationally-sampled pharmacophore describing DOR ligands,¹⁷ *N*-alkyl substitutions do not alter predicted efficacy in this same series. Applying the message-address concept,^{18,19} we hypothesize that substitution of the *N*-cyclopropylmethyl “message” of BNTX with *N*-alkyl groups satisfying the “message” (Figure 2) would enhance MOR efficacy and maintain low efficacy at DOR, resulting in MOR agonist/DOR antagonist bifunctional ligands.

N-substituent: “MOR message”:

CH₃, arylalkyl = agonist
CPM = antagonist (BNTX)

Ring C appendage: “MOR/DOR address”:
Selectivity for MOR/DOR.





Figure 2. Schematic describing the “message-address” rationale for designing bifunctional MOR agonist/DOR antagonist probes based on modification of oxymorphone. CPM = cyclopropylmethyl.

Synthesis of compounds **6** – **8** was achieved from oxycodone as shown in Scheme 1. Oxycodone (**1**) was converted to oxymorphone (**2**) using BBr₃ in the usual manner.²⁰ To synthesize *N*-substituted analogues **7** and **8**, **2** was *N*-demethylated

to noroxymorphone (**3**) using α -chloroethyl chloroformate²¹ and *N*-alkylated using the appropriate alkyl bromide. Intermediates **2**, **4**, and **5** were converted to C7-benzylidene analogues **6** – **8** under basic Claisen conditions.¹³ Purified final products were converted to water-soluble salts (HCl, oxalate) prior to pharmacologic evaluation.²²



Scheme 1. Synthesis of **6-8**. Reagents and Conditions: i) BBr_3 , CHCl_3 , 0°C , 30 min; $\text{NH}_4\text{OH}(\text{aq})$, 0°C , 30 min. ii) Ac_2O , reflux, 24 hr; 1-chloroethyl chloroformate, K_2CO_3 , $\text{Cl}(\text{CH}_2)_2\text{Cl}$, reflux, 24 hr; NaOH , MeOH , reflux, 3 hr. iii) R-Br , K_2CO_3 , RT, 24 hr. iv) PhCHO , NaOH , MeOH , 0°C , 18 hr.

OR binding results are shown in Table 1. Compound **6** bound preferentially to MOR and DOR over KOR. Affinity for MOR and DOR generally decreased as a function of *N*-arylalkyl chain length, whereas KOR affinity was improved for **7** and **8** compared to **6**. This caused a net decrease in MOR/DOR preference over KOR, similar to BNTX.¹⁴ The *N*-methyl analogue (**6**) exhibited the highest affinity for MOR and DOR of the series, approximately 3- and 20-fold greater than *N*-phenylethyl (**7**) and *N*-phenylpropyl (**8**) analogues for MOR, respectively. This was unexpected, as *N*-phenylethyl and *N*-phenylpropyl 4,5-epoxymorphinans are generally higher affinity MOR agonists than their parent *N*-methyl equivalents.^{23,24}

Table 1. K_i values of analogues **6** – **8** at MOR, DOR, KOR, and receptor selectivity ratios.

Compound	K_i (nM) \pm SEM ^a			KOR/MOR	MOR/DOR
	MOR	DOR	KOR		
6	17.5 \pm 1.10	14.4 \pm 0.65	1067 \pm 39	61	1.2
7	56.0 \pm 3.80	84.0 \pm 2.80	602 \pm 60	10.8	0.7
8	313 \pm 23	168 \pm 9.20	793 \pm 58	2.5	1.9
BNTX ^b	26	6.2	48	2	4

^aCompetition binding for compounds were performed in CHO cells stably transfected with and overexpressing the human opioid receptor types hMOR, hDOR and hKOR. Assays were performed in triplicate of duplicates and reported as mean K_i values \pm SEM. MOR was labeled using 1.3 nM [³H]DAMGO, DOR using 1.2 nM [³H]DPDPE, and KOR using 1.7 nM [³H]U69,593. K_i values for standard compounds: DAMGO (MOR, 1.5 nM), DPDPE (DOR, 2.4 nM), U69,593 (KOR, 1.1 nM).

^bData from reference¹⁴

Table 2 shows the results of a [³⁵S]GTP γ S assay to determine the relative efficacy of compounds at MOR and DOR. Compounds **6** and **7** were found to be MOR partial agonists with **6** demonstrating approximately 3-fold higher potency than **7**. Efficacy data for **8** could not be determined due to low potency. Compounds **6** and **7** possess no significant agonist activity at DOR. Compound **6** was tested further to determine DOR antagonist potency. In the GTP γ S functional assay, **6** caused a parallel rightward shift in the SNC80 concentration-response curve with K_e of 138 \pm 24 nM (Table 2). Taken together, compound **6** (benzylideneoxymorphone, UMB 246) exhibited a profile of MOR/DOR preferential binding affinity, partial agonist effects at MOR, and antagonist activity at DOR. Compound **6** was therefore selected for further characterization *in vivo*.

Table 2. EC_{50} (nM) and $\%E_{\text{max}}$ of oxymorphone analogues **6** – **8** at MOR and DOR.^a

Compound	MOR		DOR	
	EC_{50} (nM)	$\%E_{\text{max}}$	EC_{50} (nM)	$\%E_{\text{max}}$
6	72 \pm 11	39 \pm 1.3	N.D.	N.D. ^b
7	253 \pm 70	52 \pm 3.8	N.D.	< 10
8	N.D.	< 10	N.D.	N.D.

^aPercent maximal stimulation relative to standard agonist (MOR, DAMGO; DOR, DPDPE; KOR, U69,593). ^bCaused a parallel, rightward shift in SNC80 concentration-response curve using GTP γ S assay (Ke = 138 \pm 24 nM, n = 3). Tested as freebase.

Acute antinociception assays in the mouse were performed following subcutaneous (*s.c.*) administration of increasing doses of **6**.^{24,25} As shown in Figure 3, **6** produced an increase in E_{max} to approximately 40 % MPE with T_{max} of 50 min in the hot plate nociception test. Peak antinociception effects for UMB2 46 were evident at 50 minutes post-administration for the 60 mg/kg treatment group. Repeated measures ANOVA revealed a significant difference in latency for hot plate nociception testing among treatment groups ($p < 0.01$) and among time points ($p < 0.001$). Bonferroni post hoc analysis revealed that the 50 mg/kg treatment group had significantly greater antinociception, compared to saline control, at 30 ($p < 0.05$) minutes post-administration (Figure 3). Bonferroni post hoc analysis revealed that the 60 mg/kg treatment group had significantly greater antinociception, compared to saline control, at 30 ($p < 0.01$), 50 ($p < 0.001$), and 70 ($p < 0.05$) minutes post-administration.




Figure 3. Acute dose- and time-response curves for *s.c.* **6** treatment for the hot plate assay. For details, see ²⁵. Significance relative to saline control: * $p < 0.05$. ** $p < 0.01$. *** $p < 0.001$.

Figure 4 shows the results from the tail-flick nociceptive test. Peak antinociception effects for **6** were evident at 30 minutes post-administration for the 60 mg/kg treatment group. Repeated measures ANOVA revealed a significant difference in latency for tail-flick nociceptive testing among treatment groups ($p < 0.01$) and among time points ($p < 0.001$). Bonferroni post hoc analysis revealed that the 50 mg/kg treatment group had significantly greater antinociception, compared to saline control, at 70 ($p < 0.01$) minutes post-administration (Figure 4). Bonferroni post analysis revealed that the 60 mg/kg treatment group had significantly greater antinociception, compared to saline control at 30 ($p < 0.001$), 50 ($p < 0.01$), and 70 ($p < 0.01$) minutes post-administration.




Figure 4. Acute dose- and time-response curves for *s.c.* **6** treatment for the tail-flick assay. For details, see ²⁶. Significance relative to saline control: ** $p < 0.01$. *** $p < 0.001$.

The reduced opioid receptor binding affinity and potency for compounds **7** and **8** was unexpected. Introduction of the C7-benzylidene may introduce a steric effect that requires BOM to adopt an altered binding pose within MOR and DOR active sites, thereby precluding larger *N*-arylalkyl substituents.

There was some discrepancy between the K_i value (14.4 nM) and K_e value (138 nM) for **6**. Ideally, for a completely neutral antagonist these values should be the same. If taken at face value the higher K_e value obtained in more physiologically relevant buffer would suggest that **6** does have some agonist activity, albeit insufficient to show up in the stringent [^{35}S]GTP γ S assay. On the other hand the values may be reflective of the different DORs used in the assays (human versus rat) and/or the different environments in the in different cell lines employed (CHO versus C6). In summary, results presented here indicate **6** possesses a profile of MOR partial agonism and DOR antagonism *in vitro*. **6** also produces antinociception following *s.c.* administration, which suggests an ability to cross the blood-brain barrier and activate MOR *in vivo*. This initial structure-activity relationship (SAR) study shows longer-chain *N*-alkyl substituents do not enhance MOR potency as in the parent oxymorphone series. Further investigation into the structural features that improve MOR efficacy and potency in the 7-benzylideneoxymorphone series are underway and will be reported in due course.

Acknowledgments

The authors thank the National Institute on Drug Abuse, National Institutes of Health (NIDA, NIH) (A.C., DA 13583; C.W.C., DA 021049; J.R.T., DA039997). C.W.C. is grateful to Concordia University Wisconsin School of Pharmacy for financial support. J.R.H. is supported by the National Institutes of Health Postdoctoral training grant no. T32GM008562. CHO cells stably transfected to express each of the human opioid receptor types (hMOR-CHO, hDOR-CHO, hKOR-CHO cells) were generously provided by Dr. Larry Toll (Torrey Pines Institute for Molecular Studies, Port St. Lucie, FL).

References and notes

1. Institute of Medicine (US). Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. National Academy of Sciences. <http://www.nationalacademies.org/hmd/Reports/2011/Relieving-Pain-in-America-A-Blueprint-for-Transforming-Prevention-Care-Education-Research.aspx>. Accessed 28 June 2016.
2. Zieglgänsberger, W.; Tolle, R. T.; Zimprich, A.; Höllt, V.; Spanagel, R. Pain and the Brain. 1995, 22, 439.
3. Pappagallo, M. Am. J. Surg. 2001, 182(Suppl. 5A), 11S.
4. Mattick, R. P.; Kimber, J.; Breen, C.; Davoli, M. Cochrane Database Syst. Rev. 2008, 2, CD002207.
5. Zhu, Y.; King, M. A.; Schuller, A. G.; Nitsche, J. F.; Reidl, M.; Elde, R. P.; Unterwald, E.; Pasternak, G. W.; Pintar, J. E. Neuron. 1999, 24, 243.
6. Kest, B.; Lee, C. E.; McLemore, G. L.; Inturrisi, C. E. Brain Res. Bull. 1996, 39, 185.
7. Abdelhamid, E. E.; Sultana, M.; Portoghese, P. S.; Takemori, A. E. J. Pharmacol. Exp. Ther. 1991, 258, 299.
8. Schiller, P. W.; Fundytus, M. E.; Merovitz, L.; Weltrowska, G.; Nguyen, T. M.-D.; Lemieux, C.; Chung, N. N.; Coderre, T. J. J. Med. Chem. 1999, 42, 3520.
9. Ananthan, S. AAPS J. 2006, 8, E118.
10. Healy, J. R.; Bezawada, P.; Shim, J.; Jones, J. W.; Kane, M. A.; MacKerell Jr., A. D.; Coop, A.; Matsumoto, R. R. ACS Chem. Neurosci. 2013, 4, 1256.
11. Harland, A. A.; Bender, A. M.; Griggs, N. W.; Gao, C.; Anand, J. P.; Pogozeva, I. D.; Traynor, J. R.; Jutkiewicz, E. M.; Mosberg, H. I. J. Med. Chem. 2016, 59, 4985.
12. Ananthan, S.; Saini, S. K.; Dersch, C. M.; Xu, H.; McGlinchey, N.; Giuvelis, D.; Bilsky, E. J.; Rothman, R. B. J. Med. Chem. 2012, 55, 8350.
13. Portoghese, P. S.; Sultana, H.; Nagase, H.; Takemori, A. E. Eur. J. Pharmacol. 1992, 218, 195.
14. Palmer, R. B.; Uthagrove, A. L.; Nelson, W. L. J. Med. Chem. 1997, 40, 749.
15. Ohkawa, S.; Portoghese, P. S. J. Med. Chem. 1998, 41, 4177.
16. Bhargava, H. N.; Zhao, G.-M.; Bian, J.-T.; Nan, Y.; Upadhyaya, S. P.; Xu, W.; Dunn III, W. J.; Bauer, L. Peptides, 1997, 18, 695.
17. Bernard, D.; Coop, A.; Mackerell Jr., A. D. J. Med. Chem. 2007, 50, 1799.
18. Schwyzer, R. Ann. N.Y. Acad. Sci. 1977, 297, 3.
19. Portoghese, P. S. Trends Pharmacol. Sci. 1989, 10, 230.
20. Rice, K. C. J. Med. Chem. 1977, 20, 164.
21. Ninan, A.; Sainsbury, M. Tetrahedron, 1992, 48, 6709.
22. Characterization for **6**: ^1H NMR (500 MHz, CDCl_3) δ 7.65 (s, 1H), 7.26-7.37 (m, 5H), 6.75 (d, J = 8.5 Hz, 1H), 6.66 (d, J = 8.5 Hz, 1H), 4.69 (s, 1H), 3.24 (d, J = 18.5 Hz, 1H), 3.01 (d, J = 15 Hz, 1H), 2.90 (d, J = 6 Hz, 1H),

2.65 (dd, $J = 18.5$, 6 Hz, 1H), 2.50 (d, $J = 8$ Hz, 1H), 2.40 (s, 3H), 2.30-2.37 (m, 3H), 1.64 (d, $J = 11$ Hz, 1H). m/z 390.4 (M+H)⁺.

23. Casey, A. F.; Parfitt, R. T. *Opioid Analgesics*, Plenum Press: New York, 1986.
24. Haddou, B.; Beni, S.; Hosztafi, S.; Malfacini, D.; Calo, G.; Schmidhammer, H.; Spetea, M. PloS One, 9, e99231.
25. Male Swiss-Webster mice were placed within a plastic cylinder (10.8 cm ID) atop a black anodized, aluminum plate (27.9 cm x 26.7 cm x 1.9 cm) uniformly regulated at 53°C (IITC Life Science Inc., Woodland Hills, CA). Mice were treated with saline control or UMB 246 (20-60 mg/kg, s.c.)(n = 3-4 per treatment group). Latencies were recorded 30 min after drug administration and every 20 min thereafter for 90 min.
26. Male Swiss-Webster mice tails were placed underneath an overhead halogen light source (IITC Life Science Inc., Woodland Hills, CA) whereby the latency to the first sign of a rapid tail flick was determined and recorded as the behavioral endpoint. Mice were treated with saline control or UMB 246 (20-60 mg/kg, s.c.)(n = 3-4 per treatment group). Latencies were recorded 30 min after drug administration and every 20 min thereafter for 90 min.